# A Study of Long-term Treatment With Deferasirox in Patients With Beta-thalassemia and Transfusional Hemosiderosis

> **NCT00171171** · PHASE3 · COMPLETED · sponsor: **Novartis** · enrollment: 252 (actual)

## Conditions studied

- Beta-Thalassemia
- Hemosiderosis

## Interventions

- **DRUG:** deferasirox

## Key facts

- **NCT ID:** NCT00171171
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-05
- **Primary completion:** 2006-11
- **Final completion:** —
- **Target enrollment:** 252 (ACTUAL)
- **Last updated:** 2017-03-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00171171

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00171171, "A Study of Long-term Treatment With Deferasirox in Patients With Beta-thalassemia and Transfusional Hemosiderosis". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00171171. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*